In vivo analysis of signaling dynamics in the Notch interaction network

Notch 相互作用网络中信号动力学的体内分析

基本信息

项目摘要

Our program project focuses on vascular inflammation. This project focuses on Monocyte chemoattractant protein-1 (MCP-1), a pro-inflammatory CC chemokine that plays a pivotal role in recruiting monocytes/macrophages to the arterial wall, mediating both early progression of atherosclerosis and response of the arterial wall to injury. We have demonstrated that accumulation of MCP-1 in SMC is mediated in large part by changes in mRNA stability. Growth agonists, such as PDGF and angiotensin II (Ang II), increase MCP-1 mRNA half-life (t1/2) from ¿45 min to >3 hr, whereas glucocorticoids decrease the t1/2 to <15 min. Whereas PDGF and Ang II stabilize numerous mRNAs in SMC, the glucocorticoid Dexamethasone (Dex) selectively destabilizes MCP-1 mRNA. The primary goal of this project is to identify the molecules and mechanisms involved in mediating MCP-1 mRNA stability in SMC. We have made substantial progress during the current term of this award, and have demonstrated that Dex-mediated destabilization of MCP-1 mRNA involves a novel mechanism dependent upon the glucocorticoid receptor (GR). Unlike its more typical role as a transcription factor, the GR appears to be part of a degradative complex that specifically binds MCP-1 mRNA. Using an RNA affinity approach, we have identified Y-box binding protein-1 (YB-1), a multifunctional DNA and RNA binding protein with endoribonuclease properties, as a key component of this complex. We believe that we have identified a novel anti-inflammatory pathway mediated by glucocorticoids/GR that involves degradation of MCP-1 mRNA. This renewal will focus on fully elucidating this pathway. We propose 4 aims: 1) Determine the mechanism by which YB-1 and the GR mediate degradation of MCP-1 mRNA in response to Dex. 2) Identify the domains of the GR involved in regulating MCP-1 mRNA stability. 3) Identify other mediators of inflammation that are regulated in SMC by YB-1- and GR-dependent, Dex-mediated mRNA destabilization. 4) Establish that changes in mRNA stability plays an important role in mediating the effect of Dex on MCP-1 mRNA and protein in vivo. These studies may allow development of agents that mimic the potent anti-inflammatory effects of glucocorticoids without inducing their myriad side effects.
我们的项目重点是血管炎症。该项目重点研究单核细胞趋化蛋白-1 (MCP-1),这是一种促炎CC趋化因子,在募集单核/巨噬细胞到动脉壁,介导动脉粥样硬化的早期进展和动脉壁对损伤的反应中起关键作用。我们已经证明MCP-1在SMC中的积累在很大程度上是由mRNA稳定性的变化介导的。生长激动剂,如PDGF和血管紧张素II (Ang II),增加MCP-1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexey Veraksa其他文献

Alexey Veraksa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexey Veraksa', 18)}}的其他基金

Mechanisms of signal integration in developmental control of organ size and tissue patterning
器官大小和组织模式发育控制中的信号整合机制
  • 批准号:
    9326325
  • 财政年份:
    2016
  • 资助金额:
    $ 7.17万
  • 项目类别:
Mechanisms of signal integration in developmental control of organ size and tissue patterning
器官大小和组织模式发育控制中的信号整合机制
  • 批准号:
    10669132
  • 财政年份:
    2016
  • 资助金额:
    $ 7.17万
  • 项目类别:
Mechanisms of signal integration in developmental control of organ size and tissue patterning
器官大小和组织模式发育控制中的信号整合机制
  • 批准号:
    10206726
  • 财政年份:
    2016
  • 资助金额:
    $ 7.17万
  • 项目类别:
Mechanisms of signal integration in developmental control of organ size and tissue patterning
器官大小和组织模式发育控制中的信号整合机制
  • 批准号:
    10478854
  • 财政年份:
    2016
  • 资助金额:
    $ 7.17万
  • 项目类别:
Mechanisms of signal integration in developmental control of organ size and tissue patterning
器官大小和组织模式发育控制中的信号整合机制
  • 批准号:
    9918432
  • 财政年份:
    2016
  • 资助金额:
    $ 7.17万
  • 项目类别:
Mechanisms of signal integration in developmental control of organ size and tissue patterning
器官大小和组织模式发育控制中的信号整合机制
  • 批准号:
    9179040
  • 财政年份:
    2016
  • 资助金额:
    $ 7.17万
  • 项目类别:
Regulation of developmental signaling by beta-arrestin
β-抑制蛋白对发育信号的调节
  • 批准号:
    8100601
  • 财政年份:
    2011
  • 资助金额:
    $ 7.17万
  • 项目类别:
In vivo analysis of signaling dynamics in the Notch interaction network
Notch 相互作用网络中信号动力学的体内分析
  • 批准号:
    8065764
  • 财政年份:
    2010
  • 资助金额:
    $ 7.17万
  • 项目类别:
In vivo analysis of signaling dynamics in the Notch interaction network
Notch 相互作用网络中信号动力学的体内分析
  • 批准号:
    8300107
  • 财政年份:
  • 资助金额:
    $ 7.17万
  • 项目类别:

相似海外基金

Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
  • 批准号:
    10412227
  • 财政年份:
    2022
  • 资助金额:
    $ 7.17万
  • 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
  • 批准号:
    10610473
  • 财政年份:
    2022
  • 资助金额:
    $ 7.17万
  • 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
  • 批准号:
    10799162
  • 财政年份:
    2022
  • 资助金额:
    $ 7.17万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6639179
  • 财政年份:
    2001
  • 资助金额:
    $ 7.17万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6724797
  • 财政年份:
    2001
  • 资助金额:
    $ 7.17万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6636512
  • 财政年份:
    2001
  • 资助金额:
    $ 7.17万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6266928
  • 财政年份:
    2001
  • 资助金额:
    $ 7.17万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6539099
  • 财政年份:
    2001
  • 资助金额:
    $ 7.17万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6326889
  • 财政年份:
    2001
  • 资助金额:
    $ 7.17万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6520329
  • 财政年份:
    2001
  • 资助金额:
    $ 7.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了